Life Stem Genetics is Now at the Forefront of the Biggest Evolution in the Medical Treatment of Chronic Diseases

Buying LIFS now is like owning early shares in the Fountain of Youth

The crucial component to enabling a worldwide benefit from stem cell therapy is now ready:
Life Stem Genetics (LIFS)

Life Stem Genetics can fulfill the promise of Adult Stem Cell Therapies and guarantee a higher quality of life to the world!

How high can LIFS shares move from here? There is no limit and you can be certain it will be many multiples higher than the current LIFS trading level near $1. Now is the time to buy.
The stakes are too high for Big Pharma and the traditional Healthcare providers to hesitate about the current technology lead maintained by innovators like Life Stem Genetics (LIFS). It makes sense for the Bigs to simply open their acquisition check books rather than try and play catch-up!

Harvard » Bill Gates Foundation » Nobel Prize Laureates

Have Joined the Evolution with

LIFE STEM GENETICS

...to give the World Self-Healing

Life Stem Genetics (LIFS) is at the forefront of the greatest advancement of Life Science in the history of mankind. Propelled by the world’s most powerful institutions, Adult Stem Cell (ASC) therapies will enable all peoples of the world to heal themselves. Life Stem has already applied over 5,000 ASC treatments.

The Powers behind the Evolution

The amount of academic, financial and leadership strength pushing Adult Stem Cell therapies forward is relatively equivalent to that of the Age of Imperialism as the European powers became an irresistible force to colonize the “New World.” This time around, with the inevitable expansion of life sciences based on stem cells, all peoples of the world will benefit.

Harvard University holds its status as the proverbial center of the universe for stem cell research in the United States. Regenerative biologist and co-founder of the Harvard Stem Cell Institute, Dr. Douglas Melton is leading Harvard’s ascendency to world leadership in the stem cell field. Also important is Dr. Melton’s close ties with the Howard Hughes Medical Institute and its deep funding prowess.

The Bill and Melinda Gates Foundation, through its Global Alliance for Vaccines and Immunizations, is working toward the application of new stem cell technologies coupled with improved access to vital...
Life Stem Genetics (LIFS) is delivering the life-giving therapy now that can put Big $TRILLION Pharma out of business! But wait...

Big Pharma is getting into Life Stems' business - here's what to watch for:

- Pfizer’s Neusentis team developing Regenerative Medicine Portfolio
- GE Healthcare’s expanding Life Sciences division on stem cells
- Life Stem’s advance technology with micro-cap is buy-out bait!

Begin accumulating LIFS now and watch for the reactive market frenzy!

Just above $1 a share, Life Stem Genetics (LIFS) Can Become a Major Player in a Market that’s Projected to Surpass $75 BILLION NEXT YEAR!

Company: Life Stem Genetics
Symbol: LIFS
Initial Buy: IMMEDIATELY
Secondary Buy: $2 to $5
Long Term Target: $ Infinite*

* Because the projected return on investment of the global stem cell industry is already in the $Billions, I’ll wait to put a specific price target on Life Stem Genetics (LIFS) so I don’t have to keep raising it. Now is the time to make your initial buy on LIFS. Our initial valuation of Life Stem’s future market share is well above the current near $1 price level and increasing.
Dear Investor,
Solving a megatrend health problem like cancer or Alzheimer’s is one of the surest paths to wealth accumulation I know of. It’s a huge market worth tens of $Billions. Demand is 100% guaranteed as people will pay virtually anything to rescue themselves and their loved ones from these debilitating diseases.

Medical science is closing in on how to do it. Now, all YOU need to do is buy the right stock - early on - and that’s where I come in

Hello, my name is Scott Fraser, and I’ve been delivering consistent stock winners to my audience members for over 20 years - and I can tell you I have NEVER seen a stock with such enormous upside potential. And I’m including perhaps my greatest pick-to-date, Ultra Petroleum, which I recommended to my audience below $2 and later soared to over $200 per share!

Medical researchers have long since surmised that the “key” to solving the world’s most common and fatal diseases lies within our own bodies. Those researches are now being proven absolutely correct - and the share-prices of select companies are set to skyrocket.

I see Life Stem Genetics (LIFS) - currently below $2 per share - as offering individual investors the strongest upside potential with the lowest downside risk factor.

As it turns out, this medical “key” is the TRILLIONS of Adult Stem Cells (ASC’s) each and every one of us has residing within our bodies. Life Stem Genetics (LIFS) is positioned to be a global leader in Adult Stem Cell Therapies - and I see this stock going much, much higher very quickly. -Scott

POTENTIAL USES OF STEM CELLS

- Stroke
- Traumatic Brain Injury
- Learning Defects
- Alzheimer’s Disease
- Parkinson’s Disease
- Missing Teeth
- Wound Healing
- Bone Marrow Transplantation (Established)
- Spinal Cord Injury
- Osteoarthritis
- Rheumatoid Arthritis
- Baldness
- Blindness
- Deafness
- Amyotrophic Lateral Sclerosis
- Myocardial Infarction
- Muscular Dystrophy
- Diabetes
- Crohn’s Disease
HERE'S THE BIG PICTURE

Adult Stem Cell Therapies are proving highly successful at treating a wide array of neurological disorders, spinal cord and orthopedic injuries, as well as improving overall health and longevity as we age. The human body has an unparalleled ability to heal itself – far greater than any pharmaceutical or manufactured treatment ever made. Thus, it’s no wonder that the proverbial fountain of youth would be found in our OWN STEM CELLS, which, by the way are available in near limitless quantities!

ZERO CONTROVERSY!

FACT

Adult Stem Cells should NOT be confused with embryonic stem cells, which are highly controversial and regulated. Naturally, you are the rightful owner of your own stem cells and thus it is your right to be treated with them. Life Stem Genetics (LIFS) makes that possible.

REVOLUTIONIZE AGING

Stem cells are in many respects the very foundation of what it is to be human. As you’re born and begin to grow, stem cells play a vital role in the generation of new replacement cells and tissues as well as in healing and repair.
Whenever a body part or tissue becomes diseased or injured, the brain sends out chemical signals that attract stores of adult stem cells that reside in our fat, blood, tissues, and bone marrow. Our stem cells are able to morph into the cells of countless organs and structures within our own bodies. Through a process called cell division, our stem cells are able to multiply indefinitely resulting in the effective restoration of damaged structures and the rejuvenation of failing cells.

Life Stem (LIFS) is at the forefront of a groundbreaking medical therapy that could:
- Save countless lives
- Save $Billions in medical costs
- Drive LIFS shares many multiples higher!

Get on the "smartmoney" train now...

State of the Art: Life Stem’s treatment facilities offer a spa-like setting where patients undergo a 4-hour ASC treatment. Each clinic can generate up to $30 MILLION per year in revenues!

Keep in mind that the “self-harvesting” of your own Adult Stem Cells (ASC’s) for treating YOU is actually nothing new. It’s been around for decades with roughly 1 million patients in the U.S. alone being successfully treated via ASC’s since the mid-1980’s.

WHAT IS NEW...
is the “methodology” in which Adult Stem Cells are being self-harvested and then re-injected into the patient – either intravenously or via direct injection into the afflicted area.

Life Stem Genetics (LIFS) is my #1 pick for expansive shareholder gains as the company begins setting up ASC clinics all over the world utilizing its innovative Adult Stem Cell Self-Harvesting approach. Best of all, since the stem cells being used are your own, there’s zero risk of your body rejecting the treatment! The same cannot be said for embryonic stem cell procedures.

LIFE STEM’S EXPERT TEAM

Life Stem’s specialists have
And keep in mind that sports injuries and anti-aging are really just the tip of the iceberg in terms of the medical reach for Adult Stem Cell therapies. Some of the top thinktanks in medical science are now focusing their research on the potential for Adult Stem Cells to eradicate some of the worst diseases known to mankind including cancer, Alzheimer’s, and AIDS.

Funding for this research continues to grow through deep-pocketed sources such as the Howard Hughes Medical Institute and the Bill and Melinda Gates Foundation. Stem Cell therapies may also prove instrumental in treating the millions of people suffering from full or partial paralysis as a result of spinal cord injuries.

As just one example, StemCells, Inc. recently announced that the FDA has authorized an Investigational New Drug (IND) application for clinical testing of stem cells as a treatment for spinal cord injury.

"This IND is a significant step forward for our spinal cord injury program. With regulatory authorization from Switzerland, Canada and now the United States,
Life Stem Genetics (LIFS)

"we have the first international trial of a stem cell therapy for spinal cord injury."
— Stephen Huhn, MD, FACS, FAAP, Vice President, CNS Clinical Research at StemCells, Inc.

The bottom line is that Life Stem Genetics (LIFS) is in the right place → Adult Stem Cell therapies → at the right time for astute investors → around $1 per share!

That’s why I’m urging my readers to JUMP ON THIS ONE IMMEDIATELY before Wall Street drives LIFS above our current buy-ceiling.

LIFE STEM’S STOCK IS ON THE LAUNCHING PAD

My long time readers know: I’m always on the lookout for hidden stock gems in the hottest sectors – and stem cell stocks are literally scorching right now.

Stocks like Osiris Therapeutics (OSIR) with accomplishments in the Adult Stem Cell field have made early investors rich. Osiris recently soared from $4.38 to $27.40 per share.

Yet, that pales in comparison to what Life Stem’s stock can do by tackling the myriad of health issues that could be alleviated by these groundbreaking ASC treatment protocols and the company’s absolutely brilliant growth strategy.

As I write this Special Report, Life Stem Genetics (LIFS) is trading around the $1 per share level. I see LIFS as one of the “great hidden stock gems” that could return many multiples above its current price range – FAST!

When you understand what Life Stem has already accomplished and what their revenue projections are, you’ll see why I’m so excited to bring this stock to my readers just BEFORE the pending lift-off! Consider...

LIFS’s distinct Adult Stem Cell harvesting protocol is currently returning rates as high as 1.2 BILLION stem cells per sample – more than 12x the industry high!

LIFS’s expert stem cell team has performed 5,000+ ASC treatments and counting – including some of the biggest names from the NBA, NFL, MLB, and PGA!

LIFS’s clinics can generate up to $30 MILLION per year in revenues!

LIFS expects to have more than 140 affiliate and corporate locations in operation throughout the world within 5 years!
LIFS anticipates annual revenues of $111 MILLION by year-5 followed by continual revenue growth!

MARKET PENETRATION
The industry made an estimated $73.5 Billion last year. Currently, the top four areas for ASC treatments are neurological disorders, cancer, orthopedic, and dermatology.

### RANGE OF ADULT STEM CELL PROCEDURES: Therapeutic Area Market Size

<table>
<thead>
<tr>
<th>Procedure</th>
<th>2002</th>
<th>2007</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone and Joint Disorders</td>
<td>$2.3B</td>
<td>$3.5B</td>
<td>$6.8B</td>
</tr>
<tr>
<td>Cancer</td>
<td>$1.8B</td>
<td>$3.2B</td>
<td>$7.5B</td>
</tr>
<tr>
<td>Cardiovascular Disorders</td>
<td>$1.2B</td>
<td>$2.8B</td>
<td>$4.9B</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>$1.2B</td>
<td>$2.2B</td>
<td>$5.3B</td>
</tr>
<tr>
<td>Hematological Disorders</td>
<td>$1.7B</td>
<td>$2.9B</td>
<td>$5.9B</td>
</tr>
<tr>
<td>Liver Disorders</td>
<td>$1.1B</td>
<td>$1.8B</td>
<td>$1.4B</td>
</tr>
<tr>
<td>Nuerological Disorders</td>
<td>$3.3B</td>
<td>$8.1B</td>
<td>$19.8B</td>
</tr>
<tr>
<td>Skin and Wound Care</td>
<td>$1B</td>
<td>$1.7B</td>
<td>$3.5B</td>
</tr>
<tr>
<td>Urinary Incontinence</td>
<td>$500M</td>
<td>$1B</td>
<td>$2.3B</td>
</tr>
<tr>
<td>Other</td>
<td>$3.6B</td>
<td>$4.8B</td>
<td>$15.1B</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$17.7 BILLION</strong></td>
<td><strong>$32 BILLION</strong></td>
<td><strong>$73.5 BILLION</strong></td>
</tr>
</tbody>
</table>

By focusing on the rapid deployment of its evolutionary Adult Stem Cell protocol via both corporate and affiliate clinics, Life Stem Genetics (LIFS) can gain worldwide attention as a leader in the ASC treatment field.

The market in the U.S alone is...in a word...HUGE! Yet, Life Stem’s growth strategy gets even better.

"A global approach designed to maximize value for all LIFS Shareholders"

HOW?
First: Life Stem Genetics is building its base of affiliate clinics internationally from the outset. The first clinics outside the U.S. are already being planned for Hong Kong and mainland China. By gaining an international foothold early on starting with Asia, the company should be able to quickly and seamlessly expand into Europe, Canada, and Australia.
Second: Life Stem Genetics is not standing pat on just its groundbreaking Adult Stem Cell treatments. The company is already offering highly-profitable, value added treatments including: Platelet Rich Plasma Therapies, Quality Nutraceutical and Medical Supplements, IV Nutritional Cocktails, Stem Cell Banking for future treatments, and Hyperbaric Oxygen Therapy (HBOT). This should be a huge boost to the company’s bottom line.

Opportunity: One Major Story in the Press could Send LIFS Up...Up...Up!

We’re Not the Only Ones Who Realize the Value of Solving Human Disease through ASC Therapies

I think of all that Life Stem Genetics (LIFS) has accomplished — and then I remember this stock is trading around $1 per share at the time of this writing. It’s exciting to me that one of humanity’s greatest opportunities can also be one of the most profitable investments — EVER.

I don’t have to tell you what success means in the field of Adult Stem Cell therapies. The potential to successfully treat and potentially cure some of the most debilitating diseases known to man can translate to life-changing gains for well-timed, properly positioned investors.

I See Potential in Life Stem’s Stock to Enable You to Retire Years Earlier than You Planned

I believe that if you let this opportunity pass you by, you’ll regret it for years to come. Every time you hear about Life Stem Genetics (LIFS), you’ll think, “Man, I should have...” And that’s something I want you to instinctively avoid.

Rarely am I this enthusiastic about a stock — but LIFS has Huge Upside Potential written all over it. Just like Ultra Petroleum did at $2 before my readers watched it soar to over $200 per share pre-split!

Life Stem has every indicator of being our next Ultra success story. I recommend you begin picking up LIFS shares now up to our initial $2 buy-ceiling. Buy only what you’re comfortable with and then watch it. I’m confident you’ll soon be adding to your position once the story is fully revealed. I urge you to act NOW!
11/4/13
Life Stem Genetics (LIFS)

you see the immense profit potential in-play.

The Next Move is YOURS...

Timing is everything in the stock market. Wall Street operates on a “herd” mentality. Once they see something big, they all rush in at the same time. Yet, I’ve always said that the largest shareholder gains go to those with the foresight to buy early BEFORE the secret’s out — when the share-price is still at bargain basement prices. That time is NOW.

Sincerely on the Contrary,

Scott Fraser, Editor The Natural Contrarian

Symbol: LIFS
Initial Buy: IMMEDIATELY
Secondary Buy: $2 to $5
Long Term Target: $ Infinite*

*Because the projected return on investment of the global stem cell industry is already in the Billions, I’ll wait to put a specific price target on Life Stem Genetics (LIFS) so I don’t have to keep raising it. Now is the time to make your initial buy on LIFS. Our initial valuation of Life Stem’s future market share is well above the current near $1 price level and increasing.

CONTRARIAN WEALTH COALITION
We Have YOUR Profit-Key with a 100% Guarantee!

YES, FINALLY... No More Buying High then Selling Low!
There is only 1 mistake you can make in the stock market: Buying High then Selling Low. Our guidance system ensures you avoid that mistake and then PROFIT on the predictable frenzy. Plus, as part of your membership, you’ll receive other undiscovered stock opportunities like Life Stem Genetics (LIFS) plus breaking Compass Alerts on YOUR stocks!

Here is how to order:
Click on the below link and select your preferred subscription:

⇒ Best Savings! 24-month membership, just $297.
Includes 24/7 access to our world-renowned Stock-Profit Compass for 2 years. A $700 value. You save over $400!

⇒ Great Value! 12-month membership, just $165.
Includes 24/7 access to our world-renowned Stock-Profit Compass for 1 year. A $350 value. You save $185!

CLICK HERE to join our Contrarian Wealth Coalition

Your Contrarian Wealth Coalition Membership Includes:

⇒ 24/7 Access to our Stock-Profit Compass PLUS Signals on YOUR Stocks
⇒ All-Access Pass to Natural Contrarian and Situational Strategies Newsletters
⇒ Secret Trade Alerts - sent via courier
⇒ Situational Strategy Templates + Breaking Stock Updates
⇒ Exclusive Bargain-Season Buying Guide

100% Guarantee! Cancel anytime during your membership for a full refund – but understand this:
We haven’t had a refund request in over 3 years! Our proprietary playbooks are too profitable!

This publication is based exclusively on information generally available to the public and does not contain any material, non-public information. Information is obtained from sources believed to be reliable, but the information cannot be guaranteed as to its accuracy or completeness. The publisher is not, and does not purport to be, a registered investment adviser and did not accept compensation in return for this commentary. The objective of this newsletter is to present Situational Analysis and to provide progressive implementation of the author’s proprietary Situational Strategy Templates. No statement or expression of opinion, or any other matter herein, directly or indirectly, shall be construed as an offer to sell or the solicitation of an offer to buy the securities mentioned. Readers should not view this publication as offering personalized investment advice, and must individually determine the suitability of investments discussed for inclusion in their own portfolio. Past performance does not guarantee future results. Reprints or redistribution of this copyrighted material is allowed only by written permission from Contrarian Press LLC.

lifescience-wealth.com